U.S. launch expected in early February – – Niktimvo is the first and only approved treatment for chronic GVHD that targets CSF-1R to reduce the drive ...

Idorsia will conduct a proof-of-concept study for patients with vitiligo. Unique precision medicine with a dual targeting of CD8+ CXCR3+ T cells offers potential for a first-in-class targeted systemic ...

Incyte (Nasdaq:INCY) and Syndax Pharmaceuticals (Nasdaq:SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Niktimvo™ (axatilimab-csfr) in 9 mg and 22 mg vial sizes.

Heart disease and breast cancer are two of the most significant health threats facing Black women today. Here's ...

Study highlights the efficacy and safety of tildrakizumab in improving physical, psychological, and social aspects of quality ...

Not everyone is having a Dry January. But on the heels — and buzzkill — of the surgeon general’s January 3 advisory warning ...

Swollen tongue might signal deeper health concerns. Find out how it could be a warning sign for conditions like nutritional ...

Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.

People with lupus-related skin problems are more likely to develop heart disease associated with hardening of the a ...

An international committee of scientists has proposed changing the way obesity is defined and diagnosed. The proposal adds ...

Did you know that spending 20 minutes in a hot sauna three times a week can be a highly effective treatment for depression?  Randomized clinical trials have dem ...